首页> 美国卫生研究院文献>World Journal of Gastroenterology >A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study
【2h】

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

机译:口腔鱼类软骨多糖治疗铁缺乏症慢性贫血在炎症性肠病中的新无铁​​治疗:一项初步研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the effect of a new oral preparation, highly concentrated in fish cartilage, in a group of inflammatory bowel diseases (IBD) patients with chronic iron deficient anemia.METHODS: In an open label pilot study, we supple-mented a group of 25 patients (11 with Crohn’s disease and 14 with ulcerative colitis) in stable clinical conditions and chronic anemia with a food supplement which does not contain iron but contains a standardized fraction of fish cartilage glycosaminoglycans and a mixture of antioxidants (Captafer Medestea, Turin, Italy). Patients received 500 mg, twice a day during meals, for at least 4 mo. Patients were suggested to maintain their alimentary habit. At time 0 and after 2 and 4 mo, emocrome, sideremia and ferritin were examined. Paired data were analyzed with Student’s t test.RESULTS: Three patients relapsed during the study (2 in the 3rd mo, 1 in the 4th mo), two patients were lost to follow up and two patients dropped out (1 for orticaria, 1 for gastric burning). Of the remaining 18 patients, levels of serum iron started to rapidly increase within the 2nd mo of treatment, P < 0.05), whereas serum ferritin and hemoglobin needed a longer period to significantly improve their serum levels (mo 4) P < 0.05. The product was safe, easy to administer and well tolerated by patients.CONCLUSION: These data suggest a potential new treatment for IBD patients with iron deficiency chronic anemia and warrant further larger controlled studies.
机译:目的:研究高度集中于鱼软骨的新型口服制剂对一组慢性铁缺乏性贫血的炎症性肠病(IBD)患者的作用。方法:在一项开放标签的初步研究中,我们补充了一组25位患者(11位克罗恩病和14位溃疡性结肠炎)在稳定的临床情况和慢性贫血中,其食物补充剂不含铁,但含有标准比例的鱼软骨糖胺聚糖和抗氧化剂混合物(Captafer Medestea,都灵,意大利)。病人在用餐期间每天两次服用500毫克,持续至少4个月。建议患者保持饮食习惯。在时间0以及2和4个月后,检查了机场,铁血病和铁蛋白。结果:研究期间复发了3例患者(3个月中2例,第4个月中1例),其中2例患者复发。失去随访,两名患者退出(1名因荨麻疹,1名因胃灼热)。在其余18例患者中,治疗后2个月内血清铁水平开始迅速升高,P <0.05),而血清铁蛋白和血红蛋白需要更长的时间才能显着改善其血清水平( mo 4)P <0.05。该产品安全,易于管理且患者耐受性良好。结论:这些数据表明,对于缺铁性慢性贫血的IBD患者,潜在的新治疗方法值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号